Physician profile
Richard Conner
NPI 1275633364
$372,209.21
in general payments reported to CMS, 2019-2025
42 companies · $16.82 in 2025
The $16.82 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $1,045 · 2021: $40K · 2022: $72K · 2023: $212K · 2024: $46K · 2025: $16.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $257K · Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $256,610.00 |
| Food and Beverage | $680.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $366,860.00 | 2021-2024 | Npd Clinical Study |
| Intuitive Surgical, INC. | $1,003.43 | 2019-2023 | Da Vinci Surgical System |
| Dendreon Pharmaceuticals LLC | $658.39 | 2019-2022 | |
| Janssen Biotech, INC. | $450.76 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $343.66 | 2019-2022 | |
| Neotract INC. | $331.70 | 2019-2020 | |
| Pfizer INC. | $300.26 | 2019-2022 | |
| Abbvie INC. | $295.32 | 2019-2025 | Lupron Depot |
| Medtronic, INC. | $190.78 | 2021 | |
| Axonics, INC. | $148.50 | 2021-2023 | Axonics |
| Allergan, INC. | $125.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $104.17 | 2022-2023 | Lynparza, Keytruda |
| Urogen Pharma, INC. | $102.18 | 2022-2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $88.16 | 2019-2023 | Xiaflex, Aveed |
| Blue Earth Diagnostics | $88.00 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.